Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Leuk Lymphoma ; 9(6): 459-76, 1993 Apr.
Article in English | MEDLINE | ID: mdl-7687916

ABSTRACT

We have successfully constructed highly potent and selective anti-CD19 PAP immunotoxins using each of the three crosslinking agents, SPDP, LC-SPDP, or SMPT, to generate an intermolecular bridge between the B43 MoAb and PAP toxin moieties. These immunotoxins were selectively immunoreactive with and cytotoxic against CD19+ B-lineage ALL cells. In this report, we compared (a) in vivo chemical, immunological, and biological stability, (b) in vivo immunogenicity, and (c) in vivo anti-leukemic activity of various B43-PAP immunotoxin constructs. Our data recommend the use of SPDP and SMPT rather than LC-SPDP for generation of B43(anti-CD19)-PAP immunotoxins as clinical anti-leukemic agents. To our knowledge, this is the first comparative analysis of the in vivo pharmacokinetic features, immunogenicity, and anti-leukemic activity of anti-CD19 PAP immunotoxins that were prepared with different heterobifunctional crosslinking agents.


Subject(s)
Antigens, CD/immunology , Antigens, Differentiation, B-Lymphocyte/immunology , Antineoplastic Agents, Phytogenic/therapeutic use , Immunotoxins/therapeutic use , N-Glycosyl Hydrolases , Plant Proteins/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Animals , Antibodies, Monoclonal/therapeutic use , Antigens, CD19 , Drug Stability , Humans , Immunotoxins/chemistry , Immunotoxins/immunology , Mice , Mice, SCID , Rabbits , Ribosome Inactivating Proteins, Type 1 , Tumor Cells, Cultured
2.
Antimicrob Agents Chemother ; 37(4): 835-8, 1993 Apr.
Article in English | MEDLINE | ID: mdl-8494381

ABSTRACT

The ability of an alpha CD4-pokeweed antiviral protein (PAP) immunoconjugate to inhibit replication of human immunodeficiency virus type 1 (HIV-1) was evaluated in vitro with 22 clinical HIV-1 strains obtained from four seropositive asymptomatic individuals, three patients with AIDS-related complex, and four patients with AIDS. Fifteen isolates were from zidovudine-untreated individuals, whereas seven isolates were obtained after 24 to 104 weeks of therapy with zidovudine, alone or alternating with zalcitabine. Mean zidovudine 50% inhibitory concentrations (IC50s) were 126 nM (range, 1 to 607 nM) for isolates from zidovudine-untreated individuals and 2,498 nM (range, 14 to 6,497 nM) for strains from patients treated with antiretroviral agents. Mean alpha CD4-PAP IC50s were 48 x 10(-3) nM (range, 0.02 x 10(-3) to 212 x 10(-3) nM) for isolates from zidovudine-untreated individuals, and 16 x 10(-3) nM (range, 2 x 10(-3) to 28 x 10(-3) nM) for isolates from treated patients. Overall, higher concentrations of alpha CD4-PAP were necessary to inhibit HIV-1 strains from untreated individuals at more advanced stages of disease. Seventeen isolates were susceptible to zidovudine (mean IC50, 117 nM), and five were resistant to zidovudine (mean IC50, 3,724 nM). Mean alpha CD4-PAP IC50s were 43 x 10(-3) nM for zidovudine-susceptible isolates and 19 x 10(-3) nM for isolates resistant to zidovudine. All HIV-1 strains had IC50s greater than 0.5 nM for unconjugated PAP, the alpha CD19-PAP immunoconjugate, and monoclonal antibody alpha CD4. At concentrations as high as 5,000 nM, alphaCD4-PAP did not inhibit colony formation by normal bone marrow progenitor cells(BFU-E, CFU-GM , and CFU-GEMM) or myeloid cell lines (KG-1 and HL-60) and did not decrease cell viabilities of T-cell (Jurkat) or B-cell (FL-112 and Raji) precursor lines. Overall, alphaCD4-PAP demonstrated more potent anti-HIV-1 activity than zidovudine and inhibited replication of zidovudine-susceptible and zidovudine-resistant viruses at concentrations that were not toxic to lymphohematopoietic cell populations.


Subject(s)
Antiviral Agents/pharmacology , CD4 Antigens/immunology , HIV-1/drug effects , Immunotoxins/pharmacology , N-Glycosyl Hydrolases , Plant Proteins/pharmacology , AIDS-Related Complex/microbiology , Cell Line , Cell Survival/drug effects , Cytopathogenic Effect, Viral , HIV Seropositivity/microbiology , HIV-1/immunology , Humans , Ribosome Inactivating Proteins, Type 1 , Zidovudine/pharmacology
3.
Blood ; 79(12): 3369-79, 1992 Jun 15.
Article in English | MEDLINE | ID: mdl-1375851

ABSTRACT

Sequential immunophenotypes of bone marrow (BM) and peripheral blood (PBL) lymphoid cells from 15 B-lineage acute lymphoblastic leukemia (ALL) patients who underwent autologous bone marrow transplantation (BMT) during complete remission were determined by dual-color immunofluorescence and multiparameter flow cytometry. Autografts were depleted of CD19+ B-cell precursors by an immunochemopurging protocol that combines B43-PAP, a potent anti-CD19 immunotoxin, and the cyclophosphamide congener 4-hydroperoxycyclophosphamide (4-HC). A marked interpatient variation was observed in the appearance and expansion of B-cell precursors repopulating the posttransplant marrow. The expression of CD10 and CD19 antigens during early B-cell ontogeny post-BMT preceded the expression of CD20, CD21, CD22, CD40, and sIgM. The surface antigen profiles of the emerging B-cell precursors were similar to those of fetal liver or fetal bone marrow B-cell precursors. Our comparisons of BM and PBL samples from patients in the early post-BMT period demonstrated that (1) PBL initially contains fewer B-lineage cells than does BM, and (2) circulating B-lineage lymphoid cells have a more mature immunophenotype than do BM B-lineage lymphoid cells. Comparison of the surface antigen profiles of day 30 versus day 100 or year 1 BM or PBL lymphoid cells showed an increase in the percentages of CD10+CD22- undifferentiated lymphocyte precursors, as well as CD19+sIgM- B-cell precursors (pre-pre-B), consistent with a time-dependent expansion of these B-cell precursor populations post-BMT. Importantly, the percentages of CD10+CD22+ and CD19+sIgM+ B-cell precursor (pre-B) populations also increased between 30 days and 1 year post-BMT, confirming the ability of emerging immature B-cell precursors to differentiate along the B-precursor pathway. The acquisition and expression of B-lineage differentiation antigens at different stages of the post-BMT B-cell ontogeny support the notion that the expression of these antigens is developmentally programmed. Similar to patients in previous autologous BMT studies, recipients of B-cell precursor-depleted autografts had normal or nearly normal serum immunoglobulin levels, suggesting that the maturing B-cell/plasma cell populations can produce and secrete immunoglobulins. The development of a functional CD19+ B-lineage lymphoid compartment in recipients of autografts which were depleted of CD19+ B-cell precursors corroborates the previously postulated existence of CD19- B-lineage lymphoid progenitor cells.


Subject(s)
Antigens, CD/analysis , Antigens, Differentiation, B-Lymphocyte/analysis , B-Lymphocytes/immunology , Bone Marrow Purging/methods , Bone Marrow Transplantation , Hematopoietic Stem Cells/immunology , N-Glycosyl Hydrolases , Precursor Cell Lymphoblastic Leukemia-Lymphoma/surgery , Antigens, CD/immunology , Antigens, CD19 , Antigens, Differentiation, B-Lymphocyte/immunology , B-Lymphocytes/pathology , Bone Marrow/embryology , Bone Marrow Cells , Cyclophosphamide/analogs & derivatives , Flow Cytometry , Fluorescent Antibody Technique , Hematopoietic Stem Cells/pathology , Humans , Immunoglobulins/blood , Immunophenotyping , Immunotoxins , Liver/cytology , Liver/embryology , Plant Proteins , Ribosome Inactivating Proteins, Type 1 , Transplantation, Autologous
4.
Blood ; 79(10): 2649-61, 1992 May 15.
Article in English | MEDLINE | ID: mdl-1375109

ABSTRACT

We show that a highly aggressive subclone of murine BCL-1 B-lineage leukemia expresses a single 2.4-kb transcript hybridizing to the human CD19 cDNA probe and reacts strongly with the anti-human CD19 monoclonal antibodies (MoAb) B43, B4, Leu-12, and J3-119. In contrast to their strong reactivity with anti-human CD19 MoAb, BCL-1 cells show no reactivity with MoAb directed against human CD22, CD72, HLA-DR, IgD, or IgM. Western blot analysis of BCL-1 whole cell lysates with the anti-human CD19 MoAb J3-119 showed a single 69-Kd protein band, which was not detected by the negative control MoAb G19.4 (anti-CD3). In contrast to BCL-1 cells, normal BALB/c splenocytes or mouse splenocyte/myeloma hybridoma cell lines did not (1) express any transcripts that hybridized to the human CD19 cDNA probe, (2) react with B43/anti-CD19 MoAb, or (3) express the 69-Kd protein that reacts with the anti-human CD19 MoAb J3-119. Murine BCL-1 B-cell leukemia thus provides a unique model of disseminated B-lineage leukemia to evaluate the antileukemic efficacy of anti-CD19 immunotoxins. This model was subsequently used to evaluate the in vivo homing ability, pharmacokinetics, and antileukemic efficacy of B43 MoAb conjugated to the plant hemitoxin pokeweed antiviral protein (PAP). B43-PAP immunotoxin (1) showed strong and antigen-specific reactivity with BCL-1 cells, (2) promptly penetrated the spleens of leukemic mice, (3) rapidly reduced the BCL-1 leukemia burden of leukemic mice and, most importantly, (4) improved survival. Finally, B43-PAP immunotoxin was more effective against BCL-1 leukemia than 700 cGy (LD100/30) total body irradiation (TBI) followed by syngeneic bone marrow transplantation (BMT).


Subject(s)
Antigens, CD/immunology , Antigens, Differentiation, B-Lymphocyte/immunology , Immunotoxins/therapeutic use , Leukemia, B-Cell/drug therapy , Leukemia, Experimental/drug therapy , N-Glycosyl Hydrolases , Plant Proteins/therapeutic use , Animals , Antibodies, Monoclonal/therapeutic use , Antigens, CD/analysis , Antigens, CD/genetics , Antigens, CD19 , Antigens, Differentiation, B-Lymphocyte/analysis , Antigens, Differentiation, B-Lymphocyte/genetics , B-Lymphocytes/immunology , Blotting, Northern , Cell Line , Clone Cells , Female , Humans , Immunotoxins/metabolism , Leukemia/genetics , Leukemia, B-Cell/genetics , Leukemia, Experimental/genetics , Mice , Mice, Inbred BALB C , Plant Proteins/pharmacokinetics , RNA, Neoplasm/genetics , RNA, Neoplasm/isolation & purification , Ribosome Inactivating Proteins, Type 1
5.
Blood ; 77(6): 1271-82, 1991 Mar 15.
Article in English | MEDLINE | ID: mdl-1672098

ABSTRACT

T-lineage acute lymphoblastic leukemia (T-ALL) cells have abundant cytoplasmic CD3/Ti but express low amounts on the cell surface and are deficient in CD3/Ti-mediated signal transduction. Nevertheless, plating T-ALL cells on dishes containing immobilized anti-CD3 monoclonal antibodies with a source of growth factors induced the expression of CD25 (interleukin-2 receptor alpha chain) and stimulated the formation of blast colonies in 12 of 14 cases studied. The proliferative response to CD3 ligation was modulated by the presence of antibodies to the CD2, CD4, or CD8 accessory T-cell receptors. The effect of these accessory receptors on signal transduction mediated by CD3/Ti was next investigated by monitoring cytoplasmic calcium concentration [( Ca2+]i) and by measuring tyrosine phosphorylation after stimulation. Crosslinking CD3, CD2, CD4, or CD8 alone did not induce cytoplasmic calcium mobilization in T-ALLs, but crosslinking the accessory receptors with CD3/Ti induced calcium responses in three of the T-ALLs and enhanced calcium responses in three of the T-ALL cell lines, including HPB-ALL, MOLT-4, and CEM. Crosslinking CD4 but not CD2 with CD3/Ti greatly enhanced tyrosine phosphorylation of multiple substrates in comparison with crosslinking either CD4 or CD3/Ti separately on both normal mature T cells and the CEM T-ALL cell line. Thus, CD4 regulates CD3/Ti signal transduction in T-ALL cells through the tyrosine phosphorylation of substrates whereas CD2 may regulate [Ca2+]i signal transduction through a separate mechanism.


Subject(s)
Calcium/metabolism , Leukemia-Lymphoma, Adult T-Cell/metabolism , Protein-Tyrosine Kinases/metabolism , Receptors, Antigen, T-Cell/metabolism , Receptors, Cell Surface/physiology , T-Lymphocytes/ultrastructure , Antigens, Differentiation, T-Lymphocyte/metabolism , Antigens, Differentiation, T-Lymphocyte/physiology , CD2 Antigens , CD3 Complex , CD4 Antigens/metabolism , CD4 Antigens/physiology , CD8 Antigens , Cell Differentiation/drug effects , Cell Differentiation/physiology , Cell Membrane/metabolism , Cell Membrane/physiology , Cell Membrane/ultrastructure , Hematopoiesis/drug effects , Hematopoiesis/physiology , Hematopoietic Stem Cells/metabolism , Hematopoietic Stem Cells/physiology , Hematopoietic Stem Cells/ultrastructure , Humans , Leukemia-Lymphoma, Adult T-Cell/pathology , Leukemia-Lymphoma, Adult T-Cell/physiopathology , Phosphorylation/drug effects , Receptors, Antigen, T-Cell/drug effects , Receptors, Antigen, T-Cell/physiology , Receptors, Immunologic/metabolism , Receptors, Immunologic/physiology , Receptors, Interleukin-2/drug effects , Receptors, Interleukin-2/metabolism , Signal Transduction/drug effects , Signal Transduction/physiology , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism
6.
J Immunol Methods ; 136(2): 221-37, 1991 Feb 15.
Article in English | MEDLINE | ID: mdl-1705571

ABSTRACT

We describe a standardized method for the preparation and purification of a potent immunotoxin against B-lineage leukemia/lymphoma cells, constructed with the ribosome inhibitory single chain plant toxin pokeweed antiviral protein (PAP) and a murine IgG1 monoclonal antibody (MoAb) specific for the human B lineage differentiation antigen CD19 for human clinical trials. PAP was prepared from spring leaves of Phytolacca americana plants by ammonium sulfate precipitation and purified to homogeneity by successive steps of ion exchange chromatography. B43 MoAb was produced in vitro by hollow fiber technology and purified to homogeneity by affinity chromatography. PAP toxin and B43 MoAb were modified via their free amino groups prior to their intermolecular conjugation. 2-iminothiolane was used to introduce reactive sulfhydryl groups into PAP and N-succinimidyl 3-(2-pyridyldithio) propionate was used to introduce 2-pyridyl disulfide bonds into B43 MoAb. Modified PAP was reacted with modified B43 MoAb resulting in a sulfhydryl-disulfide exchange reaction and yielding disulfide linked PAP-B43 MoAb conjugates, which we refer to as B43-PAP immunotoxin. B43-PAP immunotoxin was subjected to preparative gel filtration chromatography and cation exchange chromatography to obtain a highly purified, sterile, and pyrogen-free immunotoxin preparation with less than 5% free antibody contamination and less than 0.5% free PAP contamination. The final product displayed a high affinity for and a very potent anti-leukemic activity against B lineage leukemia cells. With slight modifications, the procedures detailed in this report should be generally applicable to preparation of other PAP-MoAb conjugates for treatment of cancer or AIDS.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antigens, Differentiation, B-Lymphocyte/immunology , Antineoplastic Agents, Phytogenic/immunology , Immunotoxins , N-Glycosyl Hydrolases , Plant Proteins/immunology , Amino Acid Sequence , Antigens, CD19 , Antineoplastic Agents, Phytogenic/isolation & purification , Antineoplastic Agents, Phytogenic/therapeutic use , Blotting, Western , Chromatography, Affinity , Chromatography, Gel , Chromatography, High Pressure Liquid , Chromatography, Ion Exchange , Electrophoresis, Polyacrylamide Gel , Immunotoxins/therapeutic use , Molecular Sequence Data , Plant Proteins/isolation & purification , Plant Proteins/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Quality Control , Ribosome Inactivating Proteins, Type 1
7.
Nature ; 347(6288): 92-5, 1990 Sep 06.
Article in English | MEDLINE | ID: mdl-1975641

ABSTRACT

Functional impairment and selective depletion of CD4+ T cells, the hallmark of AIDS, are at least partly caused by human immunodeficiency virus (HIV-1) type 1 binding to the CD4 molecule and infecting CD4+ cells. It may, therefore, be of therapeutic value to target an antiviral agent to CD4+ cells to prevent infection and to inhibit HIV-1 production in patients' CD4+ cells which contain proviral DNA. We report here that HIV-1 replication in normal primary CD4+ T cells can be inhibited by pokeweed antiviral protein, a plant protein of relative molecular mass 30,000, which inhibits replication of certain plant RNA viruses, and of herpes simplex virus, poliovirus and influenza virus. Targeting pokeweed antiviral protein to CD4+ T cells by conjugating it to monoclonal antibodies reactive with CD5, CD7 or CD4 expressed on CD4+ cells, increased its anti-HIV potency up to 1,000-fold. HIV-1 replication is inhibited at picomolar concentrations of conjugates of pokeweed antiviral protein and monoclonal antibodies, which do not inhibit proliferation of normal CD4+ T cells or CD4-dependent responses. These conjugates inhibit HIV-1 protein synthesis and also strongly inhibit HIV-1 production in activated CD4+ T cells from infected patients.


Subject(s)
Antibodies, Monoclonal , Antiviral Agents/pharmacology , CD4-Positive T-Lymphocytes/microbiology , HIV-1/physiology , Immunotoxins , N-Glycosyl Hydrolases , Plant Proteins/pharmacology , Virus Replication/drug effects , Antigens, CD/immunology , Antiviral Agents/administration & dosage , CD4 Antigens/immunology , CD4-Positive T-Lymphocytes/immunology , HIV-1/drug effects , Humans , Plant Proteins/administration & dosage , Ribosome Inactivating Proteins, Type 1
SELECTION OF CITATIONS
SEARCH DETAIL
...